Your Shopping Cart Is Empty
| ✷ Report Code: A04205 | Feb 2022 | Pages: 270 | ||
| Tables: 126 | Charts: 42 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Cognitive And Memory Enhancer Drugs Market
Request Now !The global Cognitive and Memory Enhancer Drugs Market size was valued at $5,079.86 million in 2020, and is projected to reach $8,689.74 million by 2030, registering a CAGR of 5.5% from 2021 to 2030.
The overall impact of COVID-19 is negative on the global cognitive and memory enhancer drugs market, owing to decline in the number of visits to hospitals and clinics for the treatment of neurodegenerative, and these drugs are mainly used in the treatment of neurodegenerative disorders, which led to decline in demand of cognitive & enhancer drugs market. However, with the ongoing vaccinations and decreasing cases of COVID-19, the studied market is expected to regain its full potential over the forecast period.
Cognitive and memory enhancer drugs are the supplements or simply drugs that stimulate cognitive functional improvement. These are majorly used to treat patients suffering from schizophrenia, stroke, Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD) or geriatric patients. The major driving factors that drive the growth of Cognitive and Memory Enhancer Drug Market includes surg in geriatric population and rise in prevalence of memory-related disorders and neurological disorders. According to WHO, more than 46 million individuals live with dementia, which acts as an important factor influencing the growth of this market. Furthermore, ongoing clinical trials and potential drugs in pipeline are some of the other factors strengthening the growth of this market.
In addition, many benefits offered by cognitive drugs such as improved memory and reasoning propel the market growth. However, ethical issues related to the use of these drugs restrict the market growth. The global Market is segmented into product, application, and region. Depending on product, the market is categorized into Aricept, Razadyne, Namenda, Exelon, Provigil, Ritalin, Adderall, and others. The applications covered in the study include disease treatment, education, sports, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the Cognitive and Memory Enhancer Drugs Market in 2020, and North America is expected to retain its dominance throughout the forecast period.
Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans. Following its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which range from common to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement. Furthermore, the virus has high potential of lethality in geriatric population. On March 11, 2020, the World Health Organization made declared it as pandemic.
In addition, only a few vaccines have received emergency approvals for COVID-19 prevention. Thus, social distancing is observed as the most important measure to limit the spread of this disease. Furthermore, to maintain social distancing, various countries across the globe have adopted nationwide lockdowns. The overall impact of COVID-19 is negative on the global cognitive and memory enhancer drugs market, owing to decline in the number of visits to hospitals and clinics for the treatment of neurodegenerative, and these drugs are mainly used in the treatment of neurodegenerative disorders, which led to decline in demand of cognitive & enhancer drugs market. However, with the ongoing vaccinations and decreasing cases of COVID-19, the studied market is expected to regain its full potential over the forecast period. in the future.
Depending on product, the Aricept segment was the highest contributor to the cognitive and memory enhancer drug market in 2020, and this trend is expected to continue during the forecast period. This is attributed to rise in geriatric population and increase in adoption of Aricept for the treatment of neurological disorders.
By application, the disease treatment dominated the cognitive and memory enhancer drugs market in 2020, owing to increase in prevalence of neurodegenerative disorder such as Parkinson disease and Alzheimer’s disease. On the other hand, the education performance segment is estimated to exhibit a CAGR of 5.6% during the forecast period.
Region wise, North America garnered the largest revenue share in 2020, primarily due to the high burden of Alzheimer’s disease coupled with increase in aging population, huge investment in research & development activities, and launch of new products in the region.
However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period, owing to increase in prevalence of neurological disorders and presence of large patient pool are the key factors anticipating the growth of cognitive and memory enhancer drug market.
The key players operating in the global Cognitive and Memory Enhancer Drugs Market include AbbVie, Alterna Script LLC, Ceretropic, Biogen, Inc., Johnson & Johnson, Novartis International AG, Pfizer Inc., Takeda Pharmaceutical Company Ltd., Torrent Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. (Cephalon Inc.).
Key Benefits For Stakeholders
Cognitive and Memory Enhancer Drugs Market Report Highlights
| Aspects | Details |
|---|---|
| By Product |
|
| By Application |
|
| By Region |
|
| By Key Market Players |
|
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top winning strategies
3.2.2.Top investment pockets
3.3.Market share analysis, 2020
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Rapid growth of geriatric population
3.4.1.2.High incidence of neurodegenerative disorders
3.4.1.3.Benefits of smart drugs
3.4.2.Restraint
3.4.2.1.Numerous ethical issues
3.4.3.Opportunity
3.4.3.1.Effective strength of the drugs
3.4.4.Impact analyses
3.4.COVID-19 IMPACT ANALYSIS
CHAPTER 4:COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Aricept
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Exelon
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Namenda
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Razadyne
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Provigil
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
4.7.Ritalin
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country
4.8.Adderall
4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.3.Market analysis, by country
4.9.Others
4.9.1.Key market trends, growth factors, and opportunities
4.9.2.Market size and forecast, by region
4.9.3.Market analysis, by country
CHAPTER 5:COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Disease treatment
5.2.1.Market size and forecast, by type
5.2.1.1.Developmental conditions
5.2.1.1.1.Market size and forecast
5.2.1.2.Neurodegenerative disorders
5.2.1.2.1.Market size and forecast
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.Academic performance
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Athletic performance
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Others
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
CHAPTER 6:COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America market size and forecast, by country
6.2.2.1.U.S.
6.2.2.1.1.U.S. market size and forecast, by product
6.2.2.1.2.U.S. market size and forecast, by application
6.2.2.2.Canada
6.2.2.2.1.Canada market size and forecast, by product
6.2.2.2.2.Canada market size and forecast, by application
6.2.2.3.Mexico
6.2.2.3.1.Mexico market size and forecast, by product
6.2.2.3.2.Mexico market size and forecast, by application
6.2.3.North America market size and forecast, by product
6.2.4.North America market size and forecast, by application
6.3.Europe
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by country
6.3.2.1.Germany
6.3.2.1.1.Germany market size and forecast, by product
6.3.2.1.2.Germany market size and forecast, by application
6.3.2.2.France
6.3.2.2.1.France market size and forecast, by product
6.3.2.2.2.France market size and forecast, by application
6.3.2.3.UK
6.3.2.3.1.UK market size and forecast, by product
6.3.2.3.2.UK market size and forecast, by application
6.3.2.4.Italy
6.3.2.4.1.Italy market size and forecast, by product
6.3.2.4.2.Italy market size and forecast, by application
6.3.2.5.Spain
6.3.2.5.1.Spain market size and forecast, by product
6.3.2.5.2.Spain market size and forecast, by application
6.3.2.6.Rest of Europe
6.3.2.6.1.Rest of Europe market size and forecast, by product
6.3.2.6.2.Rest of Europe market size and forecast, by application
6.3.3.Europe market size and forecast, by product
6.3.4.Europe market size and forecast, by application
6.4.Asia-Pacific
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by country
6.4.2.1.Japan
6.4.2.1.1.Japan market size and forecast, by product
6.4.2.1.2.Japan market size and forecast, by application
6.4.2.2.China
6.4.2.2.1.China market size and forecast, by product
6.4.2.2.2.China market size and forecast, by application
6.4.2.3.India
6.4.2.3.1.India market size and forecast, by product
6.4.2.3.2.India market size and forecast, by application
6.4.2.4.Australia
6.4.2.4.1.Australia market size and forecast, by product
6.4.2.4.2.Australia market size and forecast, by application
6.4.2.5.South Korea
6.4.2.5.1.South Korea market size and forecast, by product
6.4.2.5.2.South Korea market size and forecast, by application
6.4.2.5.Rest of Asia-Pacific
6.4.2.5.1.Rest of Asia-Pacific market size and forecast, by product
6.4.2.5.2.Rest of Asia-Pacific market size and forecast, by application
6.4.3.Asia-Pacific market size and forecast, by product
6.4.4.Asia-Pacific market size and forecast, by application
6.5.LAMEA
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by country
6.5.2.1.Brazil
6.5.2.1.1.Brazil market size and forecast, by product
6.5.2.1.2.Brazil market size and forecast, by application
6.5.2.2.Saudi Arabia
6.5.2.2.1.Saudi Arabia market size and forecast, by product
6.5.2.2.2.Saudi Arabia market size and forecast, by application
6.5.2.3.South Africa
6.5.2.3.1.South Africa market size and forecast, by product
6.5.2.3.2.South Africa market size and forecast, by application
6.5.2.4.Rest of LAMEA
6.5.2.4.1.Rest of LAMEA market size and forecast, by product
6.5.2.4.2.Rest of LAMEA market size and forecast, by application
6.5.3.LAMEA market size and forecast, by product
6.5.4.LAMEA market size and forecast, by application
CHAPTER 7:COMPANY PROFILE
7.1.Allergan Plc.
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.AlternaScript LLC
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.3.Biogen.
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.Ceretropic
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Opreating Segmentt
7.3.4.Product portfolio
7.4.Biogen.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.Johnson & Johnson
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.Novartis International AG
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.Pfizer Inc.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.Torrent Pharmaceutical, Inc.
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.9.Takeda Pharmaceutical Company Ltd.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments
7.10.Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
LIST OF TABLES
TABLE 01.GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 02.ARICEPT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 03.EXELON MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 04.NAMENDA MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 05.RAZADYNE MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 06.PROVIGIL MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 07.RITALIN MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 08.ADDERALL MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 09.OTHERS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 10.GLOBAL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 11.EFFECT OF THE COGNITIVE AND MEMORY ENHANCER DRUGS USED FOR DISEASE TREATMENT
TABLE 12.COGNITIVE AND MEMORY ENHANCER DRUGS MARKET FOR DISEASE TREATMENT, BY TYPE, 2020–2030 ($MILLION)
TABLE 13.COGNITIVE AND MEMORY ENHANCER DRUGS MARKET FOR DISEASE TREATMENT, BY REGION, 2020–2030 ($MILLION)
TABLE 14.COGNITIVE AND MEMORY ENHANCER DRUGS MARKET FOR ACADEMIC PERFORMANCE, BY REGION, 2020–2030 ($MILLION)
TABLE 15.COGNITIVE AND MEMORY ENHANCER DRUGS MARKET FOR ATHLETIC PERFORMANCE, BY REGION, 2020–2030 ($MILLION)
TABLE 16.COGNITIVE AND MEMORY ENHANCER DRUGS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2030 ($MILLION)
TABLE 17.COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 18.NORTH AMERICA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 19.U.S. COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 20.U.S. COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 21.CANADA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 22.CANADA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 23.MEXICO COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 24.MEXICO COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 25.NORTH AMERICA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 26.NORTH AMERICA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 28.EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 29.GERMANY COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 30.GERMANY COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 31.FRANCE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 32.FRANCE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 33.UK COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 34.UK COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 35.ITALY COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 36.ITALY COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 37.SPAIN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 38.SPAIN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 39.REST OF EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 40.REST OF EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 41.EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 42.EUROPE COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 43.ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 44.JAPAN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 45.JAPAN COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 46.CHINA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 47.CHINA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 48.INDIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 49.INDIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 50.AUSTRALIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 51.AUSTRALIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
ABLE 50.SOUTH KOREA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 51.SOUTH KOREA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 52.REST OF ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 53.REST OF ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 54.ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 55.ASIA-PACIFIC COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 56.LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 57.BRAZIL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 58.BRAZIL COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 59.SAUDI ARABIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 60.SAUDI ARABIA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 61.SOUTH AFRICA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 62.SOUTH AFRICA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 63.REST OF LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 64.REST OF LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 65.LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT, 2020–2030 ($MILLION)
TABLE 66.LAMEA COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 67.ABBVIE: COMPANY SNAPSHOT
TABLE 68.ABBVIE: OPERATING SEGMENTS
TABLE 69.ABBVIE: PRODUCT PORTFOLIO
TABLE 70.ALTERNASCRIPT: COMPANY SNAPSHOT
TABLE 71.ALTERNASCRIPT: OPERATING SEGMENTS
TABLE 72.ALTERNASCRIPT: PRODUCT PORTFOLIO
TABLE 73.BIOGEN: COMPANY SNAPSHOT
TABLE 74.BIOGEN: PRODUCT PORTFOLIO
TABLE 75.CERETROPIC: COMPANY SNAPSHOT
TABLE 76.CERETROPIC: OPERATING SEGMENTS
TABLE 77.CERETROPIC: PRODUCT PORTFOLIO
TABLE 78.J&J: COMPANY SNAPSHOT
TABLE 79.J&J: OPERATING SEGMENTS
TABLE 80.J&J: PRODUCT PORTFOLIO
TABLE 81.NOVARTIS: COMPANY SNAPSHOT
TABLE 82.NOVARTIS: OPERATING SEGMENTS
TABLE 83.NOVARTIS: PRODUCT PORTFOLIO
TABLE 84.PFIZER: COMPANY SNAPSHOT
TABLE 85.PFIZER: OPERATING SEGMENTS
TABLE 86.PFIZER: PRODUCT PORTFOLIO
TABLE 87.TORRENT: COMPANY SNAPSHOT
TABLE 88.TORRENT: PRODUCT PORTFOLIO
TABLE 89.TAKEDA: COMPANY SNAPSHOT
TABLE 90.TAKEDA: OPERATING SEGMENTS
TABLE 91.TAKEDA: PRODUCT PORTFOLIO
TABLE 92.TEVA: COMPANY SNAPSHOT
TABLE 93.TEVA: OPERATING SEGMENTS
TABLE 94.TEVA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.MARKET SEGMENTATION
FIGURE 02.TOP WINNING STRATEGIES, BY YEAR, 2015-2018*
FIGURE 03.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018* (%)
FIGURE 04.TOP WINNING STRATEGIES, BY COMPANY, 2015-2018*
FIGURE 05.TOP INVESTMENT POCKETS
FIGURE 06.MARKET SHARE ANALYSIS, 2020
FIGURE 07.IMPACT ANALYSES
FIGURE 08.COMPARATIVE ANALYSIS OF ARICEPT MARKET REVENUE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 09.COMPARATIVE ANALYSIS OF EXELON MARKET REVENUE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 10.COMPARATIVE ANALYSIS OF NAMENDA MARKET REVENUE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 11.COMPARATIVE ANALYSIS OF RAZADYNE MARKET REVENUE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 12.COMPARATIVE ANALYSIS OF PROVIGIL MARKET REVENUE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF RITALIN MARKET REVENUE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF ADDERALL MARKET REVENUE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF OTHER DRUGS MARKET REVENUE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16.DEVELOPMENTAL CONDITIONS MARKET, 2020-2023 ($MILLION)
FIGURE 17.NEURODEGENERATIVE DISORDERS MARKET, 2020-2023 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF DISEASE TREATMENT MARKET REVENUE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF COGNITIVE AND MEMORY ENHANCER DRUGS MARKET FOR ACADEMIC PERFORMANCE MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF COGNITIVE AND MEMORY ENHANCER DRUGS MARKET FOR ATHLETIC PERFORMANCE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF COGNITIVE AND MEMORY ENHANCER DRUGS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 22.POPULATION STRUCTURE BY MAJOR AGE GROUPS, EU-28
FIGURE 23.ABBVIE INC: NET SALES, 2018–2020 ($MILLION)
FIGURE 24.ABBVIE INC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 25.ABBVIE INC: REVENUE SHARE BYREGION, 2020 (%)
FIGURE 26.BIOGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.BIOGEN: REVENUE SHARE BYREGION, 2020 (%)
FIGURE 28.J&J: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30.J&J: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 31.NOVARTIS: NET SALES, 2015–2017 ($MILLION)
FIGURE 32.NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33.NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 34.PFIZER: NET SALES, 2018–2020 ($MILLION)
FIGURE 35.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36.PFIZER: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 37TAKEDA: NET SALES, 2018–2020 ($MILLION)
FIGURE 38.TAKEDA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39.TAKEDA: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 40.TEVA: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 42.TEVA: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
According to the perspective of CXOs of leading companies, the adoption of cognitive and memory enhancer drugs is expected to increase in the near future, owing to high prevalence rate of neurological disorders such as Alzheimer’s, surge in geriatric population, and benefits of these drugs such as improved physical and mental performance. These drugs are used by athletics and students to boost their physical performance and enhance other functions such as reasoning skills. However, ethical issues related with the use of these drugs would restrain the market growth. For instance, most of these arguments have a religious root, but the apparent reasoning behind the opposition of such drugs is that these are unnatural. Asia-Pacific and LAMEA are expected to offer lucrative opportunities to market players throughout the forecast period. North America is expected to dominate the global market in the near future, followed by Europe.
A. The total market value of Cognitive & Memory Enhancer Drugs Market is $8,689.74 Million in 2030
A. The forecast period in the report is from 2021 to 2030
A. The market value of Cognitive & Memory Enhancer Drugsin 2020 was $ 5,079.86 million in 2020
A. The base year for the report is 2020
A. Yes, Cognitive & Memory Enhancer Drugs Market companies are profiled in the report
A. The top companies that hold the market share in Cognitive & Memory Enhancer DrugsMarket are Allergan, Inc., Novartis AG, Shire, Johnson & Johnson, Takeda Pharmaceutical Company Limited,
A. No, there is no value chain analysis provided in the OpioidsMarket report
A. The key trends in the Cognitive & Memory Enhancer DrugsMarket are increase in prevalence of nuerodegenrative disorders along with rise in elderly population are the key factors driving the market growth.t
Start reading instantly.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report